HOME > COMMENTARY
COMMENTARY
-
June 7, 2004
-
May 24, 2004
-
BULLETIN
May 24, 2004
-
Brand Equity in the Pharmaceutical Industry
March 8, 2004
-
<Special Contribution> Breakthrough Candidates from Japanese Pharmaceutical Industry in 2004 (2)
March 8, 2004
-
March 1, 2004
-
Pursuing the Value of the Japanese Pharm Industry (2)
February 9, 2004
-
<New Series> Pursuing the Value of the Japanese Pharm Industry (1)
January 19, 2004
-
<Special Contribution> Happy New Year to Japanese Pharmaceutical Stocks!
January 12, 2004
-
<Special Contribution> Global Products Enhance Dominance in Japan with Local Products Confined to Niche Markets
January 12, 2004
-
November 10, 2003
-
<Special Contribution>
November 3, 2003
-
<Special Contribution>
September 1, 2003
-
Forecasting the Hypertensives Market: A Look Five Years Ahead Sugio Seko President, Pharma Marketing Survey Research Laboratory
August 11, 2003
-
June 9, 2003
-
May 12, 2003
-
March 24, 2003
-
January 20, 2003
-
< Special Contribution >
January 13, 2003
-
BARKER ON DRUGS
December 23, 2002
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…